3 Nov 2022 , 10:56 AM
Notably, this is the second injectable product approval from Company's General Sterile Facility (F-3) which was inspected in August, 2022.
In a regulatory filing, the company stated, "The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Toradol Injection, 15 mg/mL, 30 mg/mL, and 60 mg/2 mL, of Roche Palo Alto, LLC (Roche). Ketorolac Tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain in adult patients. Refer to our label for full indication."
According to IQVIA data, Ketorolac Tromethamine Injection USP has an estimated market size of US$ 59 million for twelve months ending June 2022.
Alembic has a cumulative total of 175 ANDA approvals (151 final approvals and 24 tentative approvals) from USFDA.
At around 10:53 AM, Alembic Pharmaceuticals Ltd is currently trading at Rs650.55 per share up by Rs38.35 or 6.26% from its previous closing of Rs612.20 per share on the BSE.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.